Revvity Developing Automated Platform for Tuberculosis Testing
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
A Cenevo survey finds that while over 60% of life sciences labs are exploring or piloting AI, only 5% have deployed it in production, with integration and data quality cited as key barriers.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
Diazyme Laboratories has acquired Carolina Liquid Chemistries, integrating CLC’s chemistry systems and reagents with Diazyme’s diagnostic technologies to expand solutions for reference and clinical laboratories.
bioMérieux has acquired Accellix for about €35 million, adding rapid, automated flow cytometry to its pharmaceutical quality control portfolio for cell and gene therapy manufacturing.
The XR-Series features higher throughput and enhanced analytics to streamline daily laboratory operations.
The PTC Harmony 96 and PTC Harmony Deepwell systems are designed to provide high-performance PCR for academic and biopharma laboratories.
Labcorp has launched MyLabcorp, a mobile app that uses OpenAI models to help patients interpret lab results and track health trends. The company cites growing consumer demand for AI-powered health information and clinical context.
Emerging hazards like aerosolized chemicals and laser equipment demand upgraded protection.
The three-tube system is designed to reduce contamination risk and improve workflow by enabling expanded urine testing from a single specimen.